Finerenone

• Clinical validation study of urinary clusterin and EGF in patients with chronic kidney disease Not authorised
  2023-507449-27-00 Phase IV 5 countries Steno Diabetes Center Copenhagen
• The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) Not authorised
  2024-511325-67-00 Phase III 1 country The George Institute For Global Health
• Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting
  2025-520660-18-00 Phase IV 1 country Policlinico San Donato S.p.A.
• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults… Recruiting
  2024-519830-22-00 Phase III 13 countries Bayer AG
• FINE-START; A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the eff… Recruiting
  2025-523075-32-00 Phase III 1 country Universitair Medisch Centrum Groningen
• Finding treatments to slow the progression of chronic kidney disease Recruiting
  2024-520253-21-00 Phase III 2 countries The George Institute For Global Health
• A study to learn more about how well finerenone works, how safe it is, and how it moves into, through, and out of the body compared to place… Recruiting
  2024-519829-38-00 Phase III 13 countries Bayer AG
• A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATI… Recruiting
  2023-508874-27-00 Phase III 1 country Colorado Prevention Center
• Semaglutide and Finerenone for Kidney and Vascular Protection in CKD Recruiting
  2025-522503-18-00 Phase IV 1 country Region Midtjylland
• Urinary proteomics to guide early intervention to prevent complications in type 2 diabetes – a feasibility study Recruiting
  2024-518682-95-00 Phase IV 2 countries Steno Diabetes Center Copenhagen
• A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatme… Recruiting
  2023-508875-35-00 Phase III 7 countries Colorado Prevention Center
• CKD-bioMatch: A biomarker-targeted clinical trial to optimize treatment for patients with chronic kidney disease Recruiting
  2023-507449-27-01 Phase IV 5 countries Steno Diabetes Center Copenhagen
• The FibroCAN study Recruiting
  2024-516597-30-00 Phase II 1 country Steno Diabetes Center Copenhagen
• Effect of Treatment with Finerenone on Cardio-Renal Target Organ Damage in Patients with Type 2 Diabetes – A Randomized Trial Recruiting
  2023-504446-58-00 Phase IV 1 country Aarhus University Hospital
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 Phase III 11 countries Colorado Prevention Center
• New treatments to reduce cardiovascular disease in type 1 diabetes Recruiting
  2023-505794-32-04 Phase III 1 country Steno Diabetes Center Copenhagen
• A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin rece… Recruiting
  2023-504885-50-00 Phase III 17 countries Bayer AG
• FINESSE: Research on improving albuminuria in patients with chronic kidney disease through the use of finerenone and semaglutide. Ended
  2023-506434-69-00 Phase II 4 countries Universitair Medisch Centrum Groningen
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b… Ended
  2023-504884-17-00 Phase III 17 countries Bayer AG
• Personalized Treatment Optimization for Kidney Health in Type 2 Diabetes: A Remote Trial with Empagliflozin and Finerenone Ended
  2023-508585-15-00 Phase IV 1 country Universitair Medisch Centrum Groningen
• A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended
  2023-505857-42-00 Phase II 6 countries Novo Nordisk A/S
• A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys’ ability … Ended
  2022-503024-27-00 Phase III 4 countries Bayer AG
• Finerenone and renal oxidative stress Ended
  2023-508266-15-00 Phase III 1 country Universitaetsklinikum Erlangen AöR
• A study to compare how much of the study treatment finerenone gets into the blood when the same amount is taken in one and in two tablets in… Ended
  2022-502385-24-00 1 country Bayer AG

Showing 1–24 of 26 trials